Celldex Therapeutics (CLDX) EBITDA Margin (2010 - 2026)

Celldex Therapeutics' EBITDA Margin history runs 17 years deep, the most recent figure standing at 531926.67% for Q1 2026.

• In Q1 2026, EBITDA Margin fell 52422278.0% year-over-year to 531926.67%; the TTM figure through Mar 2026 stood at 32874.36% (down 3052581.0% YoY), while the FY2025 annual figure was 16727.83%, down 1447916.0% from the prior year.
• EBITDA Margin was 531926.67% for Q1 2026 at Celldex Therapeutics, down from 67319.01% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 1019.92% in Q4 2023 to a low of 531926.67% in Q1 2026.
• Historically, EBITDA Margin has averaged 44119.93% across 5 years, with a median of 7104.89% in 2022.
• The sharpest annual moves came in 2025 and 2026: EBITDA Margin soared 1400894 bps in 2025, then sank 52422278 bps in 2026.
• A 5-year view of EBITDA Margin shows it stood at 1557.04% in 2022, then surged by 34 bps to 1019.92% in 2023, then sank by 309 bps to 4175.83% in 2024, then sank by 1512 bps to 67319.01% in 2025, then tumbled by 690 bps to 531926.67% in 2026.
• The last three EBITDA Margin figures came in at 531926.67% (Q1 2026), 67319.01% (Q4 2025), and 7784.79% (Q2 2025), per Business Quant data.